LC_08PE patient was diagnosed as a tumor with MPE and lymph node metastasis and was resistant to the ALK-targeted drug alectinib, despite being positive for EGFR exon 19 deletion and ALK rearrangement. Here, ALK is linked to metastatic malignant neoplasm in the lymph nodes.